Clinical Trial Update: Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Genasense (oblimersen) with carboplatin and paclitaxel in uveal melanoma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Genasense (oblimersen)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-02-11